Everything tagged "medtech" across the TickerSpark archives.
Johnson & Johnson is a Buy as newer medicines and MedTech growth offset STELARA’s decline. The stock looks fairly valued to slightly attractive with strong cash generation and a broad pipeline.
The setbacks at Intuitive Surgical and HCA expose real pressure in elective procedures, but the evidence points more to coverage and payer mix than a broad healthcare demand collapse. UnitedHealth's guidance increase and Intuitive's maintained procedure outlook show why investors should separate marginal-patient exposure from underlying utilization.
DexCom is back to a cleaner growth-and-margin profile, with double-digit revenue gains, expanding profitability, and a net cash balance supporting continued investment. The main debate is whether reimbursement expansion and international growth can offset intense CGM competition.
Stryker is executing well with double-digit revenue growth, strong segment momentum, and raised 2026 EPS guidance. The stock remains a Buy, but the premium valuation argues for patience on pullbacks.
GE HealthCare offers a balanced medtech setup with a $21.8B backlog, growing pharmaceutical diagnostics, and solid free cash flow, but tariffs and margin pressure are still weighing on results.
Alcon is a steady eye-care compounder with recurring revenue, new product momentum, and a disciplined balance sheet. The stock looks constructive, but not deeply cheap, after solid FY2025 growth and a still-elevated valuation.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime